RxDoctor Payments Data

Nicole Brown

Family · Morrisville, NCNPI 1932534526

Payments from drug & device makers

$5,069in general payments, 2019–2025

Across 269 payments — averaging $18.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Lilly USA, LLC$811
  • AbbVie$796
  • Pfizer$580
  • AstraZeneca$336
  • Biohaven Pharmaceutical Holding Company Ltd.$285
  • plus $779 from 18 others

What the payments were for

  • Food & beverage$5,069100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,069 in reported general payments places this provider in the 90th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$25,537
Medicare patients
106
Services billed
300

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide41$90,087
MounjaroTirzepatide23$47,027
FarxigaDapagliflozin Propanediol22$29,879
Atrovent HfaIpratropium Bromide11$5,111
ShingrixVaricella-Zoster Ge/As01b/Pf19$4,249
PaxlovidNirmatrelvir/Ritonavir12$2,858
Fluticasone Propionate HfaFluticasone Propionate12$2,788
Atorvastatin Calcium215$1,694
Testosterone15$1,352
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$1,284
Dextroamphetamine Sulfate24$1,219
Losartan Potassium104$1,017
Metoprolol Succinate55$976
Venlafaxine Hcl ErVenlafaxine Hcl12$964
Levothyroxine Sodium76$942

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,480$90,08741 claims
Lilly USA, LLCMounjaro$811$47,02723 claims
AstraZenecaFarxiga$336$29,87922 claims
PfizerPaxlovid$580$2,85812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,522 family providers in North Carolina.

Other family in Morrisville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →